Danaher Corporation
DHRHealthcareNASDAQDiagnostics & Research · Last scanned Jul 18, 2026
Scan Results
Daily timeframeDanaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company carries a $144.26B market cap, placing it firmly in the large-cap category. The company operates through Biotechnology, Life Sciences, and Diagnostics segments.
Market Cap
$144.26B
Beta
0.82
P/E (TTM)
39.66
P/E (Fwd)
22.06
EPS (TTM)
$5.14
EPS (Fwd)
$9.24
ROE
7.1%
ROA
4.2%
Cash
$5.70B
Total Debt
$19.68B
Free CF
$4.57B
52W Change
7.2%
Annual Financials
Cash vs Debt
On the balance sheet, DHR has $5.70B in cash with $19.68B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $4.57B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 7.1% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.2% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $26.64B (2022) to $24.57B (2025).
Investors considering Danaher Corporation should weigh the typical risks associated with DHR's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Danaher Corporation's trajectory.